BETHESDA, Md., Feb. 24, 2016 /PRNewswire/ — Cannabics Pharmaceuticals Inc. (CNBX) announced today that it has filed an exclusive provisional patent application with the US Patent & Trademark Office (USPTO) on a wholly new scheme of technology for implementation of the company’s Slow Release technology for medical capsules.
Creating a natural therapy for cancer patients has become the main focus of Cannabics Pharmaceuticals R&D branch. The clinical data now being collected as well as their scientific research are targeted for the development of personalized anti-cancer treatments.
Dr. Eyal Ballan, Chief Scientist of the company remarked “This is a great opportunity to uncover the potential therapeutics of multifactorial compounds and design scientifically advanced yet natural medicine.”
About Cannabics Pharmaceuticals Inc.
Cannabics Pharmaceuticals (CNBX), a U.S based company, is dedicated to the development of Palliative and personalized Anti-Cancer treatments. The Company’s scientific focus is on harnessing the therapeutic properties of natural Cannabinoids. Cannabics’ vision is to create tailored therapies for cancer patients, utilizing advanced screening systems and bioinformatic tools. The Company’s R&D is based in Israel, where it is licensed by the Ministry of Health and involves both scientific and academic research as well as current medical clinical studies
Disclaimer:
Certain statements contained in this release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to statements identified by words such as “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “targets,” “projects” and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company’s management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and/or other studies, the challenges inherent in new product development initiatives, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, potential litigation by or against us, any governmental review of our products or practices, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our latest 10-Q Report filed on January 22nd, 2016. We undertake no duty to update any forward-looking statement or any information contained in this press release or in other public disclosures at any time.
